Last Updated: May 11, 2026

CLINICAL TRIALS PROFILE FOR AZACITIDINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for AZACITIDINE

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004062 ↗	Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1999-07-01	RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 ↗	Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer	Completed	Lucille P. Markey Cancer Center at University of Kentucky	Phase 1	1999-07-01	RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004871 ↗	Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1	2000-05-01	RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 ↗	Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 1	2000-05-01	RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 ↗	Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1	2000-05-01	RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00005598 ↗	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 2	2000-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
NCT00005598 ↗	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	Completed	University of Michigan Cancer Center	Phase 2	2000-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for AZACITIDINE

Condition Name

Chart
Table

Condition Name for AZACITIDINE
Intervention	Trials
Acute Myeloid Leukemia	195
Myelodysplastic Syndromes	105
Myelodysplastic Syndrome	87
Chronic Myelomonocytic Leukemia	48
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for AZACITIDINE
Intervention	Trials
Leukemia, Myeloid, Acute	379
Leukemia	326
Myelodysplastic Syndromes	290
Leukemia, Myeloid	271
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for AZACITIDINE

Trials by Country

Map
Table

Trials by Country for AZACITIDINE
Location	Trials
China	389
Japan	207
United Kingdom	99
Belgium	61
Korea, Republic of	53
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for AZACITIDINE
Location	Trials
Texas	198
California	135
New York	135
Illinois	93
Florida	91
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for AZACITIDINE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for AZACITIDINE
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	14
PHASE2	52
[disabled in preview]	113
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for AZACITIDINE
Clinical Trial Phase	Trials
Recruiting	249
Completed	164
Not yet recruiting	95
[disabled in preview]	189
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AZACITIDINE

Sponsor Name

Chart
Table

Sponsor Name for AZACITIDINE
Sponsor	Trials
National Cancer Institute (NCI)	106
Celgene Corporation	78
M.D. Anderson Cancer Center	65
[disabled in preview]	133
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for AZACITIDINE
Sponsor	Trials
Other	703
Industry	513
NIH	108
[disabled in preview]	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.